harmaline has been researched along with sirolimus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alessi, DR; Arthur, JS; Bain, J; Cohen, P; Elliott, M; Hastie, CJ; Klevernic, I; McLauchlan, H; Plater, L; Shpiro, N | 1 |
| Hwang, J; Kim, DJ; Laster, KV; Liu, K; Pang, M; Shi, X; Xie, X; Zhang, Y | 1 |
2 other study(ies) available for harmaline and sirolimus
| Article | Year |
|---|---|
The selectivity of protein kinase inhibitors: a further update.
Topics: Amino Acid Sequence; Animals; Cell Line; Drug Design; Enzyme Activation; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Recombinant Proteins; Spodoptera | 2007 |
Harmaline isolated from Peganum harmala suppresses growth of esophageal squamous cell carcinoma through targeting mTOR.
Topics: Cell Line, Tumor; Cell Proliferation; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Harmaline; Head and Neck Neoplasms; Humans; Peganum; Sirolimus; TOR Serine-Threonine Kinases | 2021 |